heart disease
Conditions
Interventions
Remazolam group: Intravenous remazolam is administered during the induction and maintenance phases of anesthesia
Propofol group: Intravenous propofol is administered during the induction and maintenance phases of anesthesia
Sponsors
The secone xiangya hospital of central south university
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Patients undergoing elective cardiac surgery, ASA II~III 2. AgeD 18~70 years, BMI 18.9~28.9kg/m2, no gender restrictions 3. Clearly understand and voluntarily participate in this research and sign the informed consent
Exclusion criteria
Exclusion criteria: 1. Known allergic or contraindicated to benzodiazepines, muscle relaxants and other general anesthetics 2. Severe cardiac dysfunction (EF<30%), ASA IV or above 3. Severe liver or kidney insufficiency 4. Those who have mental and cognitive dysfunction and cannot communicate normally 5. Participated in drug clinical trials as subjects in the past 3 months 6. Patients with severe angina pectoris or myocardial infarction in the past history 7. Other circumstances that the investigator thinks it is inappropriate to participate in this trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dynamic;Intraoperative awareness of the incidence; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood routine, liver and kidney function and inflammatory indicators (CRP, ESR);Muscle oxygen baseline and minimum;A bad incident;Remazolam induction dosage and total dosage;Duration of surgery, time of cardiopulmonary bypass, time of extubation, time of stay in the intensive care unit; | — |
Countries
china
Contacts
Public ContactlLzhijian
the secone xiangya hospital of central south university
Outcome results
None listed